IFAN Financial, Inc.

IFAN

US45173B1017

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 20:35:39 31/05/2024 BST			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		-.--%	-75.00%

2023	IFAN Financial, Inc. announced that it expects to receive $0.124 million in funding	CI
2019	IFAN Financial, Inc. cancelled the transaction announced on April 21, 2016	CI

IFAN Financial, Inc. Appoints John De Puy as a Director

April 10, 2015 at 11:06 am

IFAN Financial, Inc. announced that on April 8, 2015, the Board of Directors of the company appointed Mr. John De Puy as a Director of the company. Mr. De Puy has been the founder and President of OakTree Ventures, a financial services firm that specializes in capital formation. Mr. De Puy's business background includes more than 25 years as an entrepreneur, CEO, management consultant and civic leader.

He is a member Wharton Alumni Club, Los Angeles Ventures Association, Southern California Software Council, San Diego Software and Internet Council, and Association for Corporate Growth. He has also served as President and Chairman of the Board of USA Volleyball. As a Director of IFAN, he will advise the company on capital formation and marketing strategy.

Latest news about IFAN Financial, Inc.

IFAN Financial, Inc. announced that it expects to receive $0.124 million in funding	23/03/23	CI
IFAN Financial, Inc. cancelled the transaction announced on April 21, 2016	20/04/19	CI
IFAN Financial, Inc. announced that it has received $0.1 million in funding	30/04/17	CI
IFAN Financial, Inc. Accepts Resignation of Jason Aplin as Vice President and Director	29/12/16	CI
IFAN Financial, Inc. cancelled the transaction announced on May 14, 2015	13/11/16	CI
IFAN Financial, Inc. will Change its Ticker to IFAN from IFANE	29/04/16	CI
IFAN Financial, Inc. announced that it expects to receive $10 million in funding from Old Main Capital	20/04/16	CI
IFAN Financial, Inc. will Change its Ticker to IFAN from IFANE	22/01/16	CI
IFAN Financial, Inc. Auditor Raises 'Going Concern' Doubt	14/12/15	CI
IFAN Financial Hires Jason Aplin as Vice President of Sales and to Board of Directors	19/11/15	CI
IFAN Financial Inc. Enters into a Strategic Relationship with GTV Corporation	23/06/15	CI
Ken Mayer to Join IFAN Financial, Inc.'s Board of Directors	23/06/15	CI
IFAN Financial, Inc. Announces Closes Funding Agreement with Sea Otter Global Ventures, LLC	01/06/15	CI
Blue Like Neon Selects IFAN Financial, Inc. to Provide Mobile Payments Solutions	14/05/15	CI
IFAN Financial, Inc. announced that it has received $0.25 million in funding from Sea Otter Global Ventures LLC	13/05/15	CI
IFAN Financial, Inc. announced that it expects to receive $2 million in funding from Sea Otter Global Ventures.	13/05/15	CI
IFAN Financial, Inc. has Changed its Ticker to IFAN.E from IFAN	22/04/15	CI
IFAN Financial, Inc. Appoints John De Puy as a Director	10/04/15	CI
IFAN Financial, Inc. Announces Audited Consolidated Earnings Results for the Full Year Ended August 31, 2014	24/02/15	CI
IFAN Financial, Inc. Auditor Raises 'Going Concern' Doubt	15/12/14	CI
Christopher Menya to Join IFAN Financial as Director and Chief Technology Officer	11/11/14	CI
IFAN Financial, Inc. completed the acquisition of Quidme.	03/10/14	CI
Infantly Available, Inc. will Change its Ticker to IFAND from IFAN	03/09/14	CI
Infantly Available, Inc. will Change its Name to IFAN Financial, Inc	03/09/14	CI
IFAN Financial, Inc. entered into a share exchange agreement to acquire Quidme.	21/07/14	CI

Chart IFAN Financial, Inc.

Duration

Period

More charts

Company Profile

Palantir Bioceuticals, Inc., formerly IFAN Financial, Inc., is a biopharmaceutical company offering holistic solutions to mental health illnesses. The Company uses psychedelic-assisted psychotherapy (PAP), supervised use of ketamine, 3,4-Methylenedioxymethamphetamine (MDMA), psilocybin, Lysergic acid diethylamide (LSD), and ibogaine as part of elaborated psychotherapy programs.

Sector

Pharmaceuticals

More about the company